The infiltration of effector CD8+ T cells into the tumor confers a survival benefit and is predictive of a beneficial response to therapy; however, CD8+ T cells are found infrequently in the tumor microenvironment (TME) of pancreatic cancer patients [28,29,30]. Here, CD8A is linked to pancreatic neoplasm.